Artesin tablets 4mg, No. 30
Expiration Date: 05/2027
Russian Pharmacy name:
Артезин таблетки 4мг, №30
benign prostatic hyperplasia;
delayed outflow of urine and symptoms associated with benign prostatic hyperplasia;
arterial hypertension (as part of combination therapy).
Inside (can be used both in the morning and in the evening).
BPH
The recommended initial dose of Kardura is 1 mg once a day in order to minimize the possibility of postural hypotension and / or syncope (syncope) (see 'Special instructions'). Depending on the individual characteristics of urodynamic parameters and the presence of BPH symptoms, the dose can be increased to 2 mg, and then to 4 mg and up to the maximum recommended dose of 8 mg. The recommended interval for dose escalation is 1Ц2 weeks. The usual recommended dose is 2-4 mg once a day.
Arterial hypertension
The dosage ranges from 1 to 16 mg / day. Treatment is recommended to start with 1 mg once a day for 1 or 2 weeks in order to minimize the possibility of postural hypotension and / or syncope (syncope) (first dose phenomenon) (see 'Special instructions'). After taking the first dose, the patient needs to monitor blood pressure for 6-8 hours. This is required due to the possibility of the development of the phenomenon of the first dose, especially pronounced against the background of the previous intake of diuretics.
Over the next 1 or 2 weeks, the dose may be increased to 2 mg once a day. To achieve the desired decrease in blood pressure, if necessary, the daily dose should be increased gradually, observing uniform intervals up to 4 mg, 8 mg and up to a maximum of 16 mg, depending on the severity of the patient's response to taking the drug.
The usual dose is 2-4 mg once a day.
If a diuretic or other antihypertensive agent is added to the therapy, it is necessary to adjust the dose of Kardura depending on the patient's condition with its further titration under the supervision of a physician.
If therapy with Kardura was interrupted for several days, the drug should be resumed from the initial dose.
Use in elderly patients. No dose adjustment is required.
Application for renal failure. The pharmacokinetics of doxazosin in patients with renal insufficiency does not change, and the drug itself does not worsen the existing renal dysfunction, therefore, in such patients it is used in normal doses.
Application for liver failure. Care must be taken (see 'Special instructions').
Application in children. There is no experience with the use of Kardura in children.
| Pills | 1 tab. |
| active substance: | |
| doxazosin mesylate | 1.213 mg |
| 2.43 mg | |
| 4.85 mg | |
| (equivalent to 1/2/4 mg doxazosin) | |
| excipients (tablets 1 and 2 mg): sodium carboxymethyl starch - 1.2 mg; lactose monohydrate - 40 mg; MCC - 76.382 / 75.17 mg; magnesium stearate - 1.08 mg; sodium lauryl sulfate - 0.12 mg | |
| excipients (4 mg tablets): sodium carboxymethyl starch - 2.4 mg; lactose monohydrate - 80 mg; MCC - 150.35 mg; magnesium stearate - 2.16 mg; sodium lauryl sulfate - 0.24 mg |
hypersensitivity to quinazolines, doxazosin or any of the auxiliary components of the drug;
lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
age under 18;
severe hepatic impairment due to lack of experience in this category of patients;
urinary tract infections;
anuria;
progressive renal failure;
hypotension and a tendency to orthostatic disorders (including a history);
concomitant obstruction of the upper urinary tract;
stones in the bladder.
With caution: mitral and aortic stenosis, heart failure with increased minute output, right ventricular failure due to pulmonary embolism or pericardial effusion, left ventricular failure with low filling pressure, cerebrovascular accident, advanced age, concomitant use with phosphodiesterase type 5 inhibitors ( PDE-5), because symptomatic hypotension, hepatic failure may occur.